hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 12:00:33 - browse：64

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： What is microchimerism and how does it affect maternal health?

leisure time

WSS

Google and Epic fight stronger regulation of AI in health care

Prime Medicine says its gene editing passes test in monkeys

Coloradans with cystic fibrosis could lose access to Trikafta

How to convince healthy people to buy insurance

Startup Neumora takes a novel depression drug to Phase 3

Medicare proceeds with plan to claw back hospital funds

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Tori Bowie and the unacceptable rates of Black maternal death

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Sports medicine is finally prioritizing gender equality

Medicare proceeds with plan to claw back hospital funds

Supreme Court strikes down use of affirmative action

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Hepatitis C has a cure — but many Americans still lack access to it

Medicare to cover more brain scans for Alzheimer’s patients

Medicare details structure of new drug price negotiation program

In early work, researchers turn to CRISPR to treat Alzheimer's

explore

Custom gene therapy hints at new path for rare disease treatments

After Sarepta trial failure, Duchenne families brace for more debate

WHO calls for emergency meeting on new China virus, as cases spread

Key Senate panel to consider PBM, drug pricing reform package

WHO calls for emergency meeting on new China virus, as cases spread

Custom gene therapy hints at new path for rare disease treatments

hotspot

Wikipedia

leisure time

focus